Advertisement

Topics

Iovance commences LN-145 dosing in Phase II trial for cervical cancer

19:00 EDT 16 Aug 2017 | Net Resources International

US-based biotechnology firm Iovance Biotherapeutics has commenced patient dosing in its Phase II C-145-04 clinical trial of LN-145 to treat recurrent, metastatic or persistent cervical carcinoma.

Original Article: Iovance commences LN-145 dosing in Phase II trial for cervical cancer

NEXT ARTICLE

More From BioPortfolio on "Iovance commences LN-145 dosing in Phase II trial for cervical cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...